本文へ移動
cccskills
無料GitHub で公開

endo-pa-dexamethasone-suppression-test

Recommends performing a dexamethasone suppression test to evaluate for autonomous cortisol secretion in patients with primary aldosteronism and adrenal adenoma. Triggered when a clinician considers whether to perform a dexamethasone suppression test in a patient with PA and adrenal adenoma.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.0 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Perform dexamethasone suppression test in PA patients with adrenal adenoma

STEP 1 — Gather Information

Confirm PA diagnosis and adrenal adenoma on cross-sectional imaging; review medications for CYP3A4 inducers (e.g., anticonvulsants, rifampin) or agents affecting dexamethasone metabolism; check serum potassium and baseline cortisol if available; ensure patient can comply with overnight fasting and oral dexamethasone administration.
Action: If eligible, proceed to administer the dexamethasone suppression test.

STEP 2 — Rule In / Rule Out

Administer 1 mg dexamethasone orally between 23:00 and 24:00; draw serum cortisol at 08:00–09:00 the next morning.
Decision: If serum cortisol >1.8 μg/dL (50 nmol/L), rule in autonomous cortisol secretion (ACS); if ≤1.8 μg/dL, rule out ACS.

STEP 3 — Classify or Stratify

If ACS is ruled in, order confirmatory tests: 24-hour urinary free cortisol and midnight salivary cortisol; consider plasma metanephrine during adrenal venous sampling if AVS is planned for PA subtyping.
Action: Initiate follow-up testing to characterize cortisol excess severity.

STEP 4 — Decide

If follow-up tests confirm ACS, plan for perioperative stress-dose glucocorticoids due to risk of postoperative adrenal insufficiency; if ACS is ruled out, proceed with PA management per guideline (e.g., mineralocorticoid receptor antagonist or adrenalectomy).
Decision: Tailor surgical or medical approach based on cortisol secretion status.

Clinical Guardrails / Mimics / Pitfalls

Do not rely solely on the dexamethasone suppression test for Cushing syndrome diagnosis; false positives may occur with oral estrogen, obesity, major depression, alcohol use, or acute illness. False negatives are rare but possible with dexamethasone malabsorption, CYP3A4 inducers, or incorrect dosing. Do not use test results to direct PA-specific therapy; its role is to evaluate autonomous cortisol secretion only. Avoid testing in patients unable to comply with overnight protocol or with known dexamethasone hypersensitivity.

Concrete Clinical Example

A 48-year-old man with PA and a 1.1 cm right adrenal adenoma on CT undergoes dexamethasone suppression test; serum cortisol next morning is 2.0 μg/dL (>1.8). Follow-up 24-hour urinary free cortisol is 120 μg/24h (elevated) and midnight salivary cortisol is 1.2 μg/dL (high). He is diagnosed with mild autonomous cortisol secretion. Prior to laparoscopic adrenalectomy, he receives stress-dose hydrocortisone perioperatively.

Source: Primary Aldosteronism: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2025, https://doi.org/10.1210/clinem/dgaf284

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する